Rheumatoid arthritis and reproduction

Rheum Dis Clin North Am. 2007 May;33(2):319-43, vi-vii. doi: 10.1016/j.rdc.2007.01.001.

Abstract

Additional research is needed to establish the safety of biologic agents in pregnancy and lactation. The practitioner should convey information regarding the natural history of rheumatoid arthritis during pregnancy and safety issues related to pharmacotherapies to every woman of childbearing age with RA, well before conception and pregnancy, to ensure optimal outcomes.

Publication types

  • Review

MeSH terms

  • Adult
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid* / drug therapy
  • Arthritis, Rheumatoid* / immunology
  • Arthritis, Rheumatoid* / physiopathology
  • Female
  • Humans
  • Hydroxychloroquine / therapeutic use
  • Immunosuppressive Agents / therapeutic use*
  • Lactation
  • Methotrexate
  • Parity
  • Pre-Eclampsia / epidemiology
  • Pregnancy
  • Pregnancy Complications* / drug therapy
  • Pregnancy Complications* / immunology
  • Pregnancy Complications* / physiopathology
  • Pregnancy Outcome*
  • Pregnancy, High-Risk* / drug effects
  • Pregnancy, High-Risk* / physiology
  • Sulfasalazine / therapeutic use
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Antirheumatic Agents
  • Immunosuppressive Agents
  • Tumor Necrosis Factor-alpha
  • Sulfasalazine
  • Hydroxychloroquine
  • Methotrexate